Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819884 | 1.00 | SIGMAR1 (0.61) | SIGMAR1MEN1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL30831430 | 1.00 | SIGMAR1 (0.61) | SIGMAR1MEN1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL9035116 | 0.86 | SIGMAR1 (0.66) | SIGMAR1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL6891239 | 0.86 | ALDH1A1 (0.56) | SIGMAR1MEN1RAB9AKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6891236 | 0.86 | ALDH1A1 (0.56) | SIGMAR1MEN1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL4816641 | 0.85 | SIGMAR1 (0.65) | SIGMAR1L3MBTL1 | |
| SCHEMBL4816631 | 0.85 | SIGMAR1 (0.65) | SIGMAR1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9489636 | 0.83 | SIGMAR1 (0.67) | SIGMAR1 | |
| Acetic Acid SCHEMBL7529900 | 0.82 | HPGD (0.60) | SIGMAR1KMT2AL3MBTL1 | |
| SCHEMBL8092963 | 0.81 | SIGMAR1 (0.59) | SIGMAR1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2019153216-A1 | SUBSTITUTED ARYLAMINO ALCOHOL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 北京梅尔森医药技术开发有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | SIGMAR1 675/4885MEN1 873/4885RAB9A 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.